Literature DB >> 7041988

Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.

H C Walvoort, R G Slee, J F Koster.   

Abstract

A biochemical study was performed in a Lapland dog suspected of glycogen storage disease type II (acid alpha-glucosidase deficiency, Pompe's disease). Glycogen content was substantially elevated in heart and skeletal muscle but not in the liver. Severely reduced activities of acid alpha-glucosidase (EC 3.2.1.20) were found in heart, skeletal muscle, liver and cultured tongue fibroblasts. The deficiency was located in the glycoprotein fraction, which supported its lysosomal origin. The electrophorogram showed after acid incubation that the affected dog was missing the activity band, while after neutral incubation the pattern was similar to control. The obtained biochemical data are compared with the known data of the human pathology.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041988     DOI: 10.1016/0304-4165(82)90050-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Glycogen storage diseases in animals and their potential value as models of human disease.

Authors:  H C Walvoort
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

Review 2.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 3.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

4.  Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).

Authors:  H C Walvoort; J A Dormans; T S van den Ingh
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

5.  A nonsense mutation in the acid α-glucosidase gene causes Pompe disease in Finnish and Swedish Lapphunds.

Authors:  Eija H Seppälä; Arnold J J Reuser; Hannes Lohi
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.